P3-163: Identification of Neurophysiological Biomarkers of MCI Using Resting State EEG

Identification of biomarkers of early stage and prodromal Alzheimer’s disease remains a priority as it is anticipated that new investigational therapeutics may show the greatest promise of efficacy in early disease states. Increased sensitivity in identifying mild cognitive impairment (MCI) in the early stages is critical for identification and stratification of patient populations sensitive to disease modifying therapeutic intervention. A...